Skip to main content

Delay in Progression of Chronic Kidney Disease (CKD) Measure

CBE ID
3753
Endorsement Status
E&M Committee Rationale/Justification

Withdrawn by the developer due to the committee not passing the measure on evidence, a must-pass criterion.

1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
E&M Cycle Comments

Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Spring 2023 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Spring 2023 “Intent to Submit.” Battelle took over the E&M work for the Spring 2023 cycle when developers and/or stewards submitted their full measure information, which for CBE #3753, the most recent measure specifications can be found here: https://p4qm.org/sites/default/files/2023-06/3753_-_ckd_progression_delay.zip

To close out this E&M cycle, Battelle published the Spring 2023 measures for pre-evaluation public commenting, convened the E&M standing committees for their measure evaluation meetings, launched the Spring 2023 post-comment period, convened the E&M committees for the post-comment meeting, convened the CSAC to render a final endorsement decision, and executed the appeals period.

 

1.6 Measure Description

The Delay in Progression of CKD Measure is an outcome measure to assess how well providers delay progression from Stage 4 CKD to end-stage renal disease (ESRD) requiring chronic dialysis.

Measure Specs
General Information
1.7 Measure Type
1.8 Level of Analysis
1.20 Types of Data Sources